Across TCGA pan-cancer cohorts, BORCS6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BORCS6 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher BORCS6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BORCS6 expression acts as an unfavorable survival marker.

BLCA, THYM, and LIHC are the cancer types where BORCS6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.130	0.720	<.001	48	view →
THYM	OS	Median	All	0.068	0.977	<.001	24	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: BORCS6 tumor-vs-normal RNA expression · all BORCS6 data types